Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction

Stopped early · Phase 4

Conditions studied: Mammaplasty

In brief

This study will evaluate the efficacy of analgesia provided by liposomal bupivacaine (Exparel) when compared to bupivacaine HCL as a transverse abdominis plane (TAP) block in terms of discharge milestones, opioid use, costs, and patient-reported satisfaction at 12, 24, and 72 hours. The investigators propose that Exparel will lower opioid use, length of stay, and overall cost of abdominally-based autologous breast reconstruction, and will lead to greater patient satisfaction.

Key facts

Study ID

NCT02662036

Run by

Washington University School of Medicine

People needed

70

Starts

2016-02-29

Expected to finish

2018-03-08

Last updated by the study team

2019-02-18

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Scheduled for abdominal-based autologous breast reconstruction (DIEP, MS-TRAM, or TRAM).
• At least 18 years of age.
• Female.
• Able to understand and willing to sign a written informed consent document.

You may not qualify if…

• Cognitive impairment.
• History of abdominal surgery precluding free flap donor site.
• Allergy or intolerance to bupivacaine or "amide" anesthetics.
• Significant preoperative chronic pain (requiring daily narcotics) or neuropathic pain (requiring daily use of pregabalin or gabapentin) within the previous 3 months.
• Pregnant or breastfeeding.

Where it is running

• Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.